An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Poorly Differentiated Neuroendocrine Carcinomas
Latest Information Update: 06 Nov 2021
At a glance
- Drugs TLC 388 (Primary)
- Indications Colon cancer; Gastric cancer; Gastrointestinal cancer; Head and neck cancer; Malignant thymoma; Neuroendocrine carcinoma; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 01 Apr 2019 Status changed from not yet recruiting to completed.
- 03 Jun 2015 New trial record